Absent contraindications, optimal medical therapy for heart failure with preserved ejection fraction (HFpEF) should include a ...
The data provide context on the ongoing workforce shortage in heart failure, a pipeline puzzle that’s proving hard to solve.
Experts hope the FAI score can become the next big tool in personalized risk assessment, though costs remain unknown.
Better resource allocation and targeted programs will be needed to help vulnerable hospitals combat the trend.
In Part 2, Wayne Batchelor, Vinod Thourani, Megan Coylewright, Basel Ramlawi, Sammy Elmariah, and Tsuyoshi Kaneko discuss ...
More than half of US adults are eligible for primary prevention with statins, yet lipid-lowering therapies remain underused.
In a pivot from personal safety measures, the multisociety effort calls on stakeholders to pursue a modern, standardized ...
With expectations to work after hours and a growing administrative burden, some say “radical” action is needed.
This month: online GLP-1 concerns, psychological impact of wearables, sexual and gender minority health insights, and more.
The US Food and Drug Administration has approved enlicitide (Lipfendra) as the first oral PCSK9 inhibitor for reducing LDL ...
The combination therapy improved LVEF, quality of life, clinical outcomes, and more, but implementation questions remain.
The FLASH protocol, associated with less radiation than a CAC scan, should be used more often in this cohort, a researcher ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results